Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bose

Showing results (271-280 of 274) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 274 results.
Nature|March 7, 1996
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosisM Verheij, R Bose, X H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Anesthesiology|January 26, 2018
Simulation-based Assessment to Reliably Identify Key Resident Performance AttributesRichard H Blum, Sharon L Muret-Wagstaff, John R Boulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Pageof 28

Showing results (271-280 of 274) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 274 results.
Nature|March 7, 1996
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosisM Verheij, R Bose, X H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trialC H Barcenas, S A Hurvitz, J A Di Palma, et al.
Anesthesiology|January 26, 2018
Simulation-based Assessment to Reliably Identify Key Resident Performance AttributesRichard H Blum, Sharon L Muret-Wagstaff, John R Boulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Pageof 28